Details for New Drug Application (NDA): 062497
✉ Email this page to a colleague
NDA 062497 describes DOXY-LEMMON, which is a drug marketed by Teva and is included in two NDAs. Additional details are available on the DOXY-LEMMON profile page.
The generic ingredient in DOXY-LEMMON is doxycycline hyclate. There are twenty-eight drug master file entries for this compound. Seventy-four suppliers are listed for this compound. Additional details are available on the doxycycline hyclate profile page.
The generic ingredient in DOXY-LEMMON is doxycycline hyclate. There are twenty-eight drug master file entries for this compound. Seventy-four suppliers are listed for this compound. Additional details are available on the doxycycline hyclate profile page.
Summary for 062497
| Tradename: | DOXY-LEMMON |
| Applicant: | Teva |
| Ingredient: | doxycycline hyclate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | EQ 50MG BASE | ||||
| Approval Date: | Aug 23, 1984 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | EQ 100MG BASE | ||||
| Approval Date: | Jun 15, 1984 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
